A 35-year-old man with type 2 diabetes presents with fasting blood glucose of 180 mg/dL despite metformin therapy. His liver biopsy shows increased hepatic glycogen and elevated PEPCK expression. Which feature best distinguishes excessive hepatic gluconeogenesis from impaired glycolysis in this patient?

Explanation

## Distinguishing Excessive Gluconeogenesis from Impaired Glycolysis ### Clinical Context In type 2 diabetes with insulin resistance, hepatic gluconeogenesis is pathologically elevated. The key discriminator between excessive gluconeogenesis and impaired glycolysis lies in the fate of pyruvate and the activity of PEPCK. ### The Discriminating Feature: PEPCK Activity and Oxaloacetate Shunting **Key Point:** In excessive gluconeogenesis, pyruvate is preferentially shunted toward oxaloacetate and then to phosphoenolpyruvate (PEP) via PEPCK, even when pyruvate levels are normal or low. This is the hallmark of gluconeogenic dominance. | Scenario | Pyruvate Level | Oxaloacetate → PEP | Lactate | Alanine | |----------|----------------|-------------------|---------|----------| | **Excessive gluconeogenesis** | Normal/Low | ↑↑ (PEPCK active) | Normal | ↓ (substrate diverted to OAA) | | **Impaired glycolysis** | ↑↑ (accumulates) | ↓ (glycolysis blocked) | ↑↑ (Cori cycle) | ↑ (pyruvate → alanine) | **High-Yield:** PEPCK (phosphoenolpyruvate carboxykinase) is the rate-limiting enzyme of gluconeogenesis and is upregulated in insulin-resistant states. Elevated PEPCK expression with increased oxaloacetate → PEP conversion is pathognomonic for excessive gluconeogenesis. ### Why This Patient Has Excessive Gluconeogenesis 1. **Elevated PEPCK on biopsy:** Direct evidence of gluconeogenic enzyme upregulation. 2. **Fasting hyperglycemia despite metformin:** Metformin inhibits glycolysis and lactate-driven gluconeogenesis, but cannot suppress PEPCK-driven gluconeogenesis in insulin-resistant hepatocytes. 3. **Increased hepatic glycogen:** Paradoxically, in insulin resistance, the liver both produces and stores glucose due to dysregulated signaling. **Clinical Pearl:** In type 2 diabetes, hepatic glucose overproduction accounts for 90% of fasting hyperglycemia. This is driven by excessive gluconeogenesis (not impaired glycolysis), which is why GLP-1 agonists and SGLT2 inhibitors target hepatic glucose production. ### Why Other Options Are Wrong - **Increased lactate and decreased pH:** This pattern indicates impaired glycolysis or anaerobic metabolism (Cori cycle), not excessive gluconeogenesis. In gluconeogenesis, lactate is consumed, not produced. - **Elevated serum pyruvate with normal alanine:** This would suggest pyruvate accumulation (glycolytic block), not gluconeogenic shunting. In excessive gluconeogenesis, pyruvate is rapidly converted to oxaloacetate, keeping pyruvate levels low. - **Decreased glucose-6-phosphatase with G-6-P accumulation:** This would cause hypoglycemia and impaired glucose output, opposite to the clinical picture. Glucose-6-phosphatase is typically normal or upregulated in type 2 diabetes.